Ganga Pharmaceuticals Limited Share Price

Equities

GANGAPHARM6

INE615T01017

Pharmaceuticals

Market Closed - Bombay S.E. 03:30:55 24/06/2024 pm IST 5-day change 1st Jan Change
24.67 INR -.--% Intraday chart for Ganga Pharmaceuticals Limited -.--% -13.41%
Sales 2022 24.89M 298K Sales 2023 25.86M 310K Capitalization 56.58M 678K
Net income 2022 - 0 Net income 2023 - 0 EV / Sales 2022 2.44 x
Net Debt 2022 19.07M 228K Net Debt 2023 17.97M 215K EV / Sales 2023 2.88 x
P/E ratio 2022
114 x
P/E ratio 2023
144 x
Employees 16
Yield 2022 *
-
Yield 2023
-
Free-Float 24.64%
More Fundamentals * Assessed data
Dynamic Chart
Ganga Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI
Ganga Pharmaceuticals Limited announced that it has received INR 17.0625 million in funding from Lenus Finvest Pvt Ltd, Plutus Capital Management Llp CI
Ganga Pharmaceuticals Limited announced that it expects to receive INR 21 million in funding from Lenus Finvest Pvt Ltd, Plutus Capital Management Llp CI
Ganga Pharmaceuticals Board to Consider Issuing Equity, Convertible Warrants to Raise Funds MT
Ganga Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended September 30, 2023 CI
Ganga Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Ganga Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended September 30, 2022 CI
Ganga Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2022 CI
Ganga Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2021 CI
Ganga Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended September 30, 2020 CI
Ganga Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2020 CI
Ganga Pharmaceuticals Limited Announces Management Changes CI
Ganga Pharmaceuticals Limited Announces the Appointment and Re-Designation of Sanjay Kulkarni as Executive Director CI
Ganga Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2019 CI
874,550 equity shares of Ganga Pharmaceuticals Limited are subject to a Lock-Up Agreement Ending on 23-FEB-2019. CI
More news
3 months+4.98%
6 months-8.97%
Current year-13.41%
More quotes
1 month
24.67
Extreme 24.67
24.67
Current year
23.50
Extreme 23.5
27.10
1 year
7.50
Extreme 7.5
28.49
3 years
5.00
Extreme 5
28.49
5 years
5.00
Extreme 5
28.49
10 years
5.00
Extreme 5
28.49
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 11/89/11
Director of Finance/CFO - 06/18/06
Chairman 70 01/12/01
Members of the board TitleAgeSince
Chief Executive Officer 60 11/89/11
Director/Board Member 58 01/12/01
Chairman 70 01/12/01
More insiders
Ganga Pharmaceuticals Limited is an India-based company, which is engaged in the production of ayurvedic medicines. The Company is also into marketing and distribution of ayurvedic medicines. It offers ayurvedic medicines in various categories, including acidity, antidandruff, antioxidants, blood purifier and skin disorder, constipation, cough and cold, dental care, diarrhea, ear care, female tonic, hair care, hemorrhoids and piles, indigestion, iron tonic, joint pains, kidney stone, liver disorder, rejuvenation tonic, sleep inducers, and herbal cosmetics. Its products include Asuka tablets, Dendroil, Ashwo tablets - tonic for body and mind, Raktaj tablets/syrup - for skin disorders, Nirmalaya (proprietary) - relieves constipation, Khadira tablets (80 mg.) (A.S.S) - relieves cough, Danta Doshahar Manjan - gum and teeth protective, Holetrica capsule - checks diarrhea and corrects digestion, Karnaraj drops (proprietary) - ear drops, Femoherb syrup/tablets, and Mahabhrungraj oil.
More about the company
  1. Stock Market
  2. Equities
  3. GANGAPHARM6 Stock